RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
RIGEL PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $309.96M | $209.92M | $147.06M | $108.52M | $81.19M | $76.47M | $53.08M | $16.95M | – | – | 105.3% | +47.7% |
| Product sales, net | $231.98M | $144.90M | $104.29M | $76.72M | $63.01M | $61.70M | $43.77M | $13.95M | – | – | 78.8% | +60.1% |
| Contract revenues from collaborations and other | $62.03M | $34.38M | $11.49M | $39.02M | $75.73M | $46.93M | $15.52M | $30.56M | $4.48M | $20.38M | 21.1% | +80.5% |
| Release of cost share liability | $39.98M | $0 | $0 | – | – | – | – | – | – | – | 13.6% | – |
| Delivery of drug supplies, royalties and others | $19.05M | $20.38M | $11.41M | $6.09M | $3.30M | – | – | – | – | – | 6.5% | -6.5% |
| Development Milestones | $3.00M | $0 | $75.00K | $25.00M | $1.88M | $2.10M | $5.50M | – | $4.23M | $20.09M | 1.0% | – |
| Government contracts | $265.00K | $0 | $1.10M | $4.50M | $10.50M | – | – | – | – | – | 0.1% | – |
| License revenue | $0 | $14.00M | $0 | $7.93M | $70.55M | $40.36M | $8.70M | $30.56M | $250.00K | – | 0.0% | -100.0% |
| Discounts and allowances | -$77.98M | -$65.02M | -$42.76M | -$31.81M | -$18.18M | -$14.77M | -$9.31M | -$3.01M | – | – | -26.5% | +19.9% |
| Research and development services | – | – | – | – | – | – | – | – | – | $290.00K | – | – |
| TAVALISSE | – | – | – | – | – | – | – | – | $0 | – | – | – |
| Research and development services and others | – | – | – | $6.09M | $3.30M | $4.47M | $1.32M | – | – | – | – | – |
| REZLIDHIA | – | – | – | $900.00K | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Rigel Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.